Publications View
Regulation of Bcl-2 family proteins by posttranslational modifications.
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Authors: Authors: Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A.
Blood
View full abstract on Pubmed
Blood
View full abstract on Pubmed
Diagnosing and exploiting cancer's addiction to blocks in apoptosis.
Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?
Rational design of therapeutics targeting the BCL-2 famil: Are some cancer cells primed for death but waiting for a final push?
Authors: Authors: Del Gaizo Moore VD, Letai A
Programmed Cell Death in Cancer Progression and Therapy
Programmed Cell Death in Cancer Progression and Therapy
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Authors: Authors: Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A.
Cancer Res
View full abstract on Pubmed
Cancer Res
View full abstract on Pubmed
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
Authors: Authors: Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A.
Cancer Cell
View full abstract on Pubmed
Cancer Cell
View full abstract on Pubmed
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Authors: Authors: Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.
J Clin Invest
View full abstract on Pubmed
J Clin Invest
View full abstract on Pubmed
Restoring cancer's death sentence.
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.
Authors: Authors: Goldsmith KC, Liu X, Dam V, Morgan BT, Shabbout M, Cnaan A, Letai A, Korsmeyer SJ, Hogarty MD.
Oncogene
View full abstract on Pubmed
Oncogene
View full abstract on Pubmed